NewcelX updates presentation to highlight diabetes program collaboration

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. ANT
3. SPY
4. FFAI
5. FFR
6. META
7. FICO
8. CART
9. LLY
10. TSLA

Go back to NewcelX updates presentation to highlight diabetes program collaboration

NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference

April 20, 2026 7:37 AM EDT

ZURICH, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (Nasdaq: NCEL), NewcelX Ltd. (Nasdaq: NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, today announced the release of an updated corporate presentation that includes the companys strategic collaboration with Eledon Pharmaceuticals (Nasdaq: ELDN) and highlights the advancement of its flagship Type 1 Diabetes program, NCEL-101, as a central pillar of the companys development strategy.

The updated presentation outlines the integration of NewcelXs scalable stem-cell-derived islet replacement platform with Eledons investigational anti-CD40L monoclonal antibody tegoprubart, a... More